{"entity":{"id":"jason-westin","kind":"person","name":"Jason R. Westin","aka":[],"tldr":"Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma.","summary":"Jason Westin was first author of the ZUMA-7 overall survival report, which showed axicabtagene ciloleucel improves survival compared with standard chemoimmunotherapy and transplant in primary refractory or early relapsed large B-cell lymphoma, the first randomised survival benefit for a CAR-T therapy and the trial that moved CAR-T into second line. He leads the Smart Start precision-medicine trials in DLBCL and lymphoma clinical research at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%20JR%5BAuthor%5D%20axicabtagene%20ZUMA-7"}],"tags":["lymphoma","car-t","second-line"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["axicabtagene-ciloleucel"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["zuma-7"],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-7-axi-cel-second-line-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Lymphoma Clinical Research, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Large B-cell lymphoma","CAR T-cell therapy","Second-line therapy","Precision medicine in lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%20JR%5BAuthor%5D%20axicabtagene%20ZUMA-7"}],"papers":[{"title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma (ZUMA-7)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2301665"},{"title":"Smart Start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.00597"},{"title":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2116133","doi":"10.1056/NEJMoa2116133"}]},"route":"/people/jason-westin/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"paper":[{"id":"paper-belinda-tisagenlecleucel-second-line-nejm-2022","kind":"paper","name":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","route":"/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}